Study of Befotertinib with Bevacizumab or Platinum-based Chemotherapy Before Surgery in Patients With Resectable Locally Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer

What this Trial Is About

Researchers are evaluating treatments for patients with resectable stage II to IIIA non-small cell lung cancer NSCLC who have an EGFR mutation. The trial compares neoadjuvant therapies combining befotertinib with either bevacizumab or platinum-based double chemotherapy. This phase 2, randomized controlled trial aims to understand how these combinations affect tumor response before surgery. Participants will receive one of two study treatments befotertinib combined with bevacizumab or befotertinib combined with platinum-based double chemotherapy. These treatments are given prior to surgery to shrink tumors and allow for radical surgery. The study is designed to assess major pathologic response up to 4 months after treatment and includes follow-up for longer-term outcomes. During the study, participants will undergo regular assessments including imaging scans CT, PET-CT, MRI, tumor measurements, and laboratory tests to monitor tumor response and organ function. Researchers will track outcomes such as objective response rate, progression-free survival, disease-free survival, overall survival, and adverse events over up to 60 months. The trial involves signing informed consent and requires good lung function to tolerate surgery, with safety monitoring throughout the study period.

Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer